Price Comparison: Urgotul AG vs Acticoat 7
I cannot provide specific pricing information for Urgotul AG versus Acticoat 7 based on the available evidence, as none of the provided studies or guidelines contain direct cost comparison data between these two silver dressings.
What the Evidence Shows About Costs
The available literature does not include pricing data for either Urgotul AG or Acticoat 7 specifically. The evidence provided focuses on clinical efficacy, safety, and wound healing outcomes rather than acquisition costs 1, 2, 3, 4, 5.
Limited Cost Information Available
- One guideline mentions general cost considerations for wound dressings, stating that dressing selection should be based on "exudate control, comfort, and cost" but provides no specific pricing 6
- A cost comparison table for actinic keratosis treatments exists but is irrelevant to burn/wound dressings 6
- Studies comparing Urgotul SSD (a related product) to standard silver sulfadiazine reported "comparable total cost" at approximately $52 USD for Urgotul SSD versus $45 USD for silver sulfadiazine, but this is not the same product as Urgotul AG 1
Clinical Performance Context (Not Price)
While I cannot answer your pricing question, the evidence does show:
- Acticoat demonstrated antimicrobial effectiveness with less frequent burn wound sepsis compared to silver nitrate (5 vs 16 cases) and reduced pain during dressing removal 3
- Urgotul-based silver dressings showed comparable healing efficacy to other silver dressings with good tolerance and reduced pain during dressing changes 1, 2, 4, 5
How to Obtain Actual Pricing
To get accurate pricing information, you would need to:
- Contact medical supply distributors directly for current wholesale/institutional pricing
- Check your facility's purchasing contracts and formulary pricing
- Review manufacturer suggested retail pricing (MSRP) from Laboratoires Urgo (Urgotul AG) and Smith & Nephew (Acticoat 7)
- Consider that pricing varies significantly by region, purchase volume, and institutional contracts
The clinical literature consistently omits specific product pricing, focusing instead on clinical outcomes, which limits evidence-based cost comparison.